Leukocare
Leukocare AG is a German biotechnology company providing data-science-driven formulation development and CMC services to biopharmaceutical companies developing biologics, ATMPs, antibodies, viral vectors, and mRNA therapeutics, leveraging proprietary AI/ML platforms including SMART Formulation and ExPreSo.
- Company typePrivate
- Founded2003
- HeadquartersMartinsried, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Leukocare does
Leukocare AG is a German biotechnology company, founded in 2003 and headquartered in Martinsried near Munich, that provides data-science-driven drug product formulation development and CMC services to pharmaceutical and biotechnology companies. Its core offerings include formulation development for antibodies, bispecifics, antibody-drug conjugates, viral vectors, mRNA therapeutics, vaccines, and gene therapies, with a particular emphasis on biologics and advanced therapy medicinal products (ATMPs). The company is recognized for achieving room-temperature or refrigerated (2–8°C) stability for gene therapy products via lyophilization, removing the need for ultra-cold storage below -60°C.
The company's technology stack is anchored by three proprietary platforms: SMART Formulation, a data-science-guided excipient screening platform that compresses formulation timelines from months to weeks; ExPreSo (Excipient Prediction Software), a machine-learning model trained on data from over 300 protein/peptide therapeutics that ranks likely stable excipients from protein sequence input; and Predictive Stability Analytics, which uses kinetic modeling and ML to forecast degradation pathways and shelf-life. These tools are supported by bioinformatics, molecular modeling, and database solutions, and the company holds 350+ stable drug-product recipes developed over more than 20 years of operation. Named customers include BioNTech, Xellia, and Formycon.
Leukocare operates a B2B professional services revenue model on a project-based, quote-driven pricing structure, with multi-year contracts typically scoped to IND or BLA regulatory milestones. The go-to-market is consultative and science-first, combining direct enterprise sales with conference-driven thought leadership (e.g., NextGen Biomed 2026, Drug Delivery Summit USA 2026), technical content marketing, and webinars. The company maintains its German headquarters and a US laboratory operation in Milford, Massachusetts opened in 2021 to support North American biopharma partners. The company is privately held, having raised USD 17.5 million in a 2021 round led by Petrichor Healthcare Capital Management.
Leukocare firmographics
Firmographics- Name
- Leukocare
- Legal name
- Leukocare AG
- Website
- https://leukocare.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Leukocare AG is a German biotechnology company providing data-science-driven formulation development and CMC services to biopharmaceutical companies developing biologics, ATMPs, antibodies, viral vectors, and mRNA therapeutics, leveraging proprietary AI/ML platforms including SMART Formulation and ExPreSo.
- Ownership category
- akta.pro rank
Leukocare industry classification
Industry- Product category
- Biopharmaceutical Formulation Development Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Leukocare is headquartered
LocationHeadquarters
- HQ city
- Martinsried
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Leukocare business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Contract Development Services: B2B professional services model providing drug product and formulation development services to pharmaceutical and biotechnology companies. Services include formulation development, analytical characterization, lyophilization cycle development, tech transfer support, and CMC regulatory submission support. Revenue is project-based, typically scoped for specific IND or BLA milestones.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing for formulation development services |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Leukocare product offering
Product offeringCore offering
Leukocare is a contract development organization (CDO) providing biopharmaceutical formulation development and drug product development services for pharmaceutical and biotechnology companies. The company combines proprietary data-science tools (SMART Formulation, ExPreSo, Predictive Stability Analytics) with wet-lab formulation, analytical characterization, lyophilization cycle development, and CMC regulatory support to deliver IND- and BLA-ready drug product packages for antibodies, ADCs, viral vectors, mRNA, and gene therapy programs.
Product overview
Leukocare is a leading provider of drug product and formulation development services for the pharmaceutical and biotechnology industries. The company operates as a platform-plus-services model built around its proprietary SMART Formulation® data-science-guided platform, which combines AI/ML-driven excipient screening with advanced analytics. Core products include SMART Formulation® for rapid formulation development, ExPreSo (Excipient Prediction Software) for machine learning-based excipient selection, and Predictive Stability Analytics for forecasting degradation pathways. The service portfolio encompasses lyophilization (freeze-drying) formulation for gene therapy stability, antibody formulation services, and integrated CMC (Chemistry, Manufacturing, and Controls) services supporting IND and BLA submissions. The company leverages over 20 years of experience and has delivered 350+ stable drug-product recipes for clients including BioNTech, Xellia, and Formycon.
Differentiator
Problem solved
Functional benefit
Products and services
- SMART Formulation Data-science-guided excipient screening platform that delivers robust, low-viscosity formulations in weeks rather than months, cutting traditional buffer development panels. Used by biopharma formulation teams developing biologics.
- ExPreSo (Excipient Prediction Software) Machine learning solution that analyzes protein sequences of drug substances and outputs ranked lists of common excipients by likelihood of producing stable formulations. Trained on data from over 300 protein/peptide therapeutics. Used by formulation scientists to reduce trial-and-error excipient preselection.
- Predictive Stability Analytics Kinetic-modelling and machine-learning analytics that forecast degradation pathways and shelf-life of biologic formulations before the first real-time stability study finishes. Used by drug product teams to accelerate development decisions.
- Lyophilization (Freeze-Drying) Formulation Development Methodical, data-driven lyophilized formulation development for gene therapy products, including degradation pathway analysis, AI-guided excipient optimization, lyophilization cycle development, and regulatory submission packaging. Enables storage at refrigerated (2-8°C) or room temperatures instead of ultra-cold storage. Used by gene therapy developers.
- Antibody and Antibody Formats Formulation Services Formulation development services for antibody and antibody formats (including bispecifics and ADCs) that help biopharma teams identify the best drug candidates early and streamline the development journey.
- Drug Product Development Services Integrated end-to-end drug-product development services for biopharma clients, covering formulation development, bioinformatics, analytical characterization, and technology transfer in support of IND and BLA submissions.
Companies that use Leukocare
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Leukocare technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Leukocare partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights5 records
Leukocare competitors and assessment
Company assessmentBroad incumbents
- BioReliance (MilliporeSigma): MilliporeSigma's biopharmaceutical services arm offering biosafety testing, process development, and formulation support for biologics and cell/gene therapies. Adjacent capability set with overlapping biopharma customer base.
- Catalent: Major global CDMO with deep formulation, softgel, biologics, and cell therapy capabilities, including predictive and data-driven formulation services. Overlaps with Leukocare's biologics and gene therapy formulation offering.
- AGC Biologics: Global CDMO with broad biologics, cell therapy, and mRNA development and manufacturing services. Competes with Leukocare in formulation and process development for biologics and ATMPs at much larger scale.
- Lonza: World's largest CDMO offering biologics, cell and gene therapy, and mRNA services including formulation development. Represents the dominant scaled competitor against which Leukocare's specialized formulation expertise is positioned.
Direct peers
- Rentschler Biopharma: German-headquartered biologics CDMO offering formulation development, process development, and manufacturing for mAbs and recombinant proteins. Closest geographic and capability match to Leukocare's biologics formulation focus.
- Cytovance Biologics: US-based biologics CDMO offering microbial and mammalian process development, formulation, and analytical services. Comparable in scale and capability profile to Leukocare's contract development services.
- Vibalogics: Specialized viral vector and oncolytic virus CDMO offering process and formulation development for gene therapies. Direct comparable for Leukocare's viral vector and AAV formulation/lyophilization services.
- Genezen: US-based viral vector and gene therapy CDMO focused on lentivirus, AAV, and process/formulation development. Comparable to Leukocare's US-based viral vector formulation services out of Milford, MA.
Regional players
- Aragen Life Sciences: India-based CRO/CDMO offering biologics formulation, analytical, and process development services. Comparable in service scope but serves primarily a different geographic market than Leukocare's EMEA/US focus.
Others
- Bio-Techne: Life sciences tools and services provider with formulation-related reagents and analytics capabilities. Comparable at the level of supporting biologics formulation and stability workflows, though not a direct services competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights3 records
Customer concentration
Leukocare social profiles
Digital presenceLeukocare financial estimates
Financial estimateRevenue estimate
Valuation estimate
Leukocare leadership team
Management profileNumber of profiles
Profiles3 records
Leukocare funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Leukocare M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Leukocare
What does Leukocare do?
Leukocare is a contract development organization (CDO) providing biopharmaceutical formulation development and drug product development services for pharmaceutical and biotechnology companies. The company combines proprietary data-science tools (SMART Formulation, ExPreSo, Predictive Stability Analytics) with wet-lab formulation, analytical characterization, lyophilization cycle development, and CMC regulatory support to deliver IND- and BLA-ready drug product packages for antibodies, ADCs, viral vectors, mRNA, and gene therapy programs.
Is Leukocare a public or private company?
Leukocare is a private company. It is classified as venture growth investor backed and is currently operating.
When was Leukocare founded?
Leukocare was founded in 2003. It employs 11 to 50 people.
Where is Leukocare based?
Leukocare is headquartered in Martinsried, Germany, in the Europe region.
How does Leukocare make money?
One revenue line is on record: contract Development Services.
Who are Leukocare's main competitors?
Broad incumbents on record are BioReliance (MilliporeSigma), Catalent, AGC Biologics and Lonza. Direct peers are Rentschler Biopharma, Cytovance Biologics, Vibalogics and Genezen. Aragen Life Sciences is listed as a regional player. Bio-Techne is listed as an others.
Does Leukocare have an API?
No public API is recorded for Leukocare.
What industry is Leukocare in?
Leukocare's product category is Biopharmaceutical Formulation Development Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO. Its NAICS code is 541714 and its SIC code is 8731.